AbbVie / Genmab – European Approval of TEPKINLY + R2 in R/R Follicular Lymphoma

Summary The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory follicular lymphoma. The approval is supported by the Phase 3 EPCORE FL-1 trial, where TEPKINLY + R2 reduced the risk of disease progression or death…